Applied Therapeutics Past Earnings Performance
Past criteria checks 0/6
Applied Therapeutics's earnings have been declining at an average annual rate of -19.9%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 56% per year.
Key information
-19.9%
Earnings growth rate
20.0%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 56.0% |
Return on equity | -3,179.1% |
Net Margin | 88,353.8% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation
Nov 15Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review
Sep 18Applied Therapeutics: Pushing Towards FDA Approval
Sep 04We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely
Aug 01Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases
May 28Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible
Feb 16Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?
Feb 16Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?
Nov 13We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate
Aug 11We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate
May 19Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock
Jan 19Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?
Nov 11Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation
Aug 13Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorder
Jun 17Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?
May 15Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)
Feb 26How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?
Feb 18Applied Therapeutics to resume galactosemia study for AT-007
Feb 02Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Have Been Selling
Nov 24Applied Therapeutics EPS misses by $0.21
Nov 12Revenue & Expenses Breakdown
How Applied Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 0 | -187 | 40 | 0 |
30 Jun 24 | 0 | -161 | 29 | 0 |
31 Mar 24 | 0 | -194 | 24 | 0 |
31 Dec 23 | 10 | -120 | 21 | 0 |
30 Sep 23 | 11 | -97 | 22 | -44 |
30 Jun 23 | 11 | -73 | 24 | -30 |
31 Mar 23 | 11 | -70 | 25 | -15 |
31 Dec 22 | 0 | -83 | 27 | 0 |
30 Sep 22 | 0 | -95 | 32 | 59 |
30 Jun 22 | 0 | -105 | 36 | 64 |
31 Mar 22 | 0 | -105 | 41 | 63 |
31 Dec 21 | 0 | -106 | 43 | 63 |
30 Sep 21 | 0 | -102 | 42 | 61 |
30 Jun 21 | 0 | -104 | 41 | 63 |
31 Mar 21 | 0 | -106 | 37 | 69 |
31 Dec 20 | 0 | -94 | 33 | 62 |
30 Sep 20 | 0 | -88 | 27 | 62 |
30 Jun 20 | 0 | -69 | 21 | 49 |
31 Mar 20 | 0 | -49 | 17 | 33 |
31 Dec 19 | 0 | -46 | 13 | 32 |
30 Sep 19 | 0 | -35 | 10 | 24 |
30 Jun 19 | 0 | -28 | 7 | 19 |
31 Mar 19 | 0 | -23 | 3 | 17 |
31 Dec 18 | 0 | -17 | 2 | 11 |
Quality Earnings: APLT is currently unprofitable.
Growing Profit Margin: APLT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: APLT is unprofitable, and losses have increased over the past 5 years at a rate of 19.9% per year.
Accelerating Growth: Unable to compare APLT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APLT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: APLT has a negative Return on Equity (-3179.06%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 00:34 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Applied Therapeutics, Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Brian Skorney | Baird |
Carter Gould | Barclays |
Catherine Seifert | CFRA Equity Research |